Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EXAS Exact Sciences Corp
- Stocks
- Healthcare
- NASDAQ: EXAS
Price (delayed)
$53.4
Market cap
$10.07B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.54
Enterprise value
$12.25B
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first
Highlights
The company's quick ratio has surged by 63% YoY and by 20% QoQ
EXAS's revenue is up by 12% year-on-year and by 2.5% since the previous quarter
The company's equity fell by 23% YoY
Key stats
What are the main financial stats of EXAS
Market
Valuations
Earnings
Shares outstanding
188.64M
Market cap
$10.07B
Enterprise value
$12.25B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.14
Price to sales (P/S)
3.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.33
Revenue
$2.83B
Gross profit
$1.95B
Operating income
-$1.04B
Net income
-$1.02B
EBIT
-$999.68M
EBITDA
-$758.08M
Free cash flow
$194.14M
Per share
Balance sheet
Liquidity
EPS
-$5.54
EPS diluted
-$5.54
Free cash flow per share
$1.04
Book value per share
$12.9
Revenue per share
$15.14
TBVPS
$12.61
Total assets
$5.71B
Total liabilities
$3.31B
Debt
$2.52B
Equity
$2.4B
Working capital
$867.88M
Debt to equity
1.05
Current ratio
2.73
Quick ratio
2.12
Net debt/EBITDA
-2.87
Margins
Efficiency
Dividend
EBITDA margin
-26.8%
Gross margin
69%
Net margin
-36.1%
Operating margin
-36.7%
Return on assets
-16.3%
Return on equity
-36.4%
Return on invested capital
-25%
Return on capital employed
-19.2%
Return on sales
-35.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXAS stock price
How has the Exact Sciences stock price performed over time
Intraday
3.43%
1 week
0.13%
1 month
20.13%
1 year
-0.21%
YTD
-4.97%
QTD
23.35%
Financial performance
How have Exact Sciences's revenue and profit performed over time
Revenue
$2.83B
Gross profit
$1.95B
Operating income
-$1.04B
Net income
-$1.02B
Gross margin
69%
Net margin
-36.1%
EXAS's revenue is up by 12% year-on-year and by 2.5% since the previous quarter
EXAS's gross profit is up by 11% year-on-year
The company's net margin rose by 3.2% QoQ
The operating margin has increased by 3.4% since the previous quarter
Price vs fundamentals
How does EXAS's price correlate with its fundamentals
Growth
What is Exact Sciences's growth rate over time
Valuation
What is Exact Sciences stock price valuation
P/E
N/A
P/B
4.14
P/S
3.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.33
The company's equity fell by 23% YoY
The stock's price to book (P/B) is 18% more than its last 4 quarters average of 3.5 but 6% less than its 5-year quarterly average of 4.4
EXAS's price to sales (P/S) is 50% less than its 5-year quarterly average of 7.0
EXAS's revenue is up by 12% year-on-year and by 2.5% since the previous quarter
Efficiency
How efficient is Exact Sciences business performance
The ROE has contracted by 6% from the previous quarter
Exact Sciences's ROS has increased by 3.6% from the previous quarter
The company's return on invested capital rose by 3.1% QoQ
Dividends
What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXAS.
Financial health
How did Exact Sciences financials performed over time
The total assets is 72% more than the total liabilities
EXAS's current ratio has soared by 66% YoY and by 27% QoQ
The company's quick ratio has surged by 63% YoY and by 20% QoQ
The company's debt is 5% higher than its equity
EXAS's debt to equity is up by 28% year-on-year but it is down by 9% since the previous quarter
The company's equity fell by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.